Drug intelligence / Profile preview

NDC-002A

Development stage: Unknown
Lead developer: DR.Noah Biotech
Modality: Small Molecules
Administration: Oral

Overview

NDC-002A is a component of the combination drug NDC-002, developed by Dr. Noah Biotech as an AI-designed therapy for stroke recovery and dementia. NDC-002 comprises at least two agents, and NDC-002A is one of the individual drugs studied for its safety, tolerability, pharmacokinetics, and drug interaction profile. The combination aims to reduce neuroinflammation, minimize brain damage, and promote neuronal differentiation and recovery in damaged brain areas. Mechanistic details specific to NDC-002A are not publicly available, but the overall effect of the combination is to improve outcomes after neurological injury, especially stroke[1][2].

Brand names: NDC-002ANDC002ANDC 002A
Other names: NDC-002ANDC002ANDC 002A

Beyond the preview

Go deeper on NDC-002A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDC-002A.

Explore the full profile